Omnicell Inc (OMCL)

Industry Health Information Services


This stock can be held in an Investment ISA and an Investment Account
Sell

$20.00

Buy

$45.96

arrow-up$0.73 (+2.61%)

Prices updated at 14 May 2025, 09:00 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing.

Income statement

20232024
1,147m1,112m
497m471m
-35m337,000
-3.040.03
-20m13m
61m90m
Sales, General and administrative435m380m
Interest expenses--
Provision for income taxes263,00013m
Operating expenses532m471m
Income before taxes-20m26m
Net income available to common shareholders-20m13m
-0.450.27
Net interest income15m25m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)-0.450.27
Free cash flow per share3.66512.5794
Book value/share26.075126.5475
Debt equity ratio0.507650.158866

Balance sheet

20232024
Current assets928m815m
Current liabilities368m596m
Total capital1,759m1,410m
Total debt614m383m
Total equity1,189m1,243m
Total non current liabilities--
Loans570m166m
Total assets2,227m2,121m
Total liabilities--
Cash and cash equivalents468m369m
Common stock46m46m

Cash flow

20232024
Cash at beginning of period353m501m
Cash dividends paid--
126m135m
Investments (gains) losses-55m-53m
501m399m
Net income--
181m188m
-55m-53m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.